Abstract:Increased matrix stiffness within the colorectal cancer (CRC) tumor microenvironment (TME) has emerged as a pivotal determinant of immunotherapy outcomes. This review discusses the role of aberrant extracellular matrix (ECM) deposition and cross-linking in augmenting matrix stiffness, a phenomenon that not only scaffolds the tumor architecture but also contributes to tumorigenicity and immunologic evasion. Herein, we critically appraise the influence of matrix stiffness on the immunotherapeutic landscape of CRC, focusing on its capacity to impede therapeutic efficacy by modulating immune cell infiltration, activation, and functional performance. The review explores the molecular dynamics whereby matrix stiffness prompts tumor evolution, highlighting the integral role of integrin signaling, cancer-associated fibroblasts (CAFs), and the process of epithelial-mesenchymal transition (EMT). We bring to the fore the paradoxical impact of an indurated ECM on immune effector cells, chiefly T cells and macrophages, which are indispensable for immune surveillance and the execution of immunotherapeutic strategies, yet are markedly restrained by a fibrotic matrix. Furthermore, we examine how matrix stiffness modulates immune checkpoint molecule expression, thereby exacerbating the immunosuppressive milieu within the TME and attenuating immunotherapeutic potency. Emergent therapeutic regimens targeting matrix stiffness-including matrix modulators, inhibitors of mechanotransduction signaling pathways, and advanced biomaterials that mimic the ECM-proffer novel modalities to potentiate immunotherapy responsiveness. By refining the ECM's biomechanical attributes, the mechanical barriers posed by the tumor stroma can be improved, facilitating robust immune cell penetration and activity, and thereby bolstering the tumor's susceptibility to immunotherapy. Ongoing clinical trials are evaluating these innovative treatments, particularly in combination with immunotherapies, with the aim of enhancing clinical outcomes for CRC patients afflicted by pronounced matrix stiffness.

Targeting extracellular matrix stiffness for cancer therapy

Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy

The Role of Matrix Stiffness in Cancer Stromal Cell Fate and Targeting Therapeutic Strategies

Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer

Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy

The key role of matrix stiffness in colorectal cancer immunotherapy: mechanisms and therapeutic strategies

Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy

Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion

The Mechanical Problems in Tumor and Tumor Microenvironment

Understanding and measuring mechanical signals in the tumor stroma

Extracellular matrix remodeling in the tumor immunity

Extracellular matrix and its therapeutic potential for cancer treatment

Targeting Extracellular Matrix Interaction in Gastrointestinal Cancer: Immune Modulation, Metabolic Reprogramming, and Therapeutic Strategies

Tissue Elasticity Bridges Cancer Stem Cells to the Tumor Microenvironment Through Micrornas: Implications for a ″Watch-and-wait″ Approach to Cancer

Mechano-mediated M2 macrophage polarization and immune suppression in stiffened tumor microenvironment

Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment

3D Microenvironment Stiffness Regulates Tumor Spheroid Growth and Mechanics via p21 and ROCK

Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment

Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium

Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?